ArticleFrontiers in human neuroscience2024
Neuromuscular impairments of cerebral palsy: contributions to gait abnormalities and implications for treatment.
Article in Frontiers in human neuroscience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Rewiring the Senses: The Impact of Sensory Integration Therapy on Balance and Cognition in Cerebral Palsy.Occupational therapy international · 2026Trial
- The effect of GIP and GLP-2 on bone turnover in children with cerebral palsy or spinal muscular atrophy.Journal of the Endocrine Society · 2026Article
- Activation Duty Cycle and Regional Muscle Co-Activation Across GMFCS Levels in Ambulatory Children with Spastic Cerebral Palsy: An Exploratory Surface EMG Study.Sensors (Basel, Switzerland) · 2026Article
- Can slow and (un)steady still win the race? A narrative review of developmental gait characteristics and clinical implications in children born preterm.European journal of pediatrics · 2026Review
- Inter-Limb Asymmetry and Its Limited Role in Physical Performance and Match Demands in Football Players with Spastic Hemiparesis-An Exploratory Team Study.Journal of functional morphology and kinesiology · 2026Article
- The gait performance, sensorimotor cortical activation and their correlation during walking task among children with cerebral palsy: a fNIRS study.BMC pediatrics · 2026Article
- How Do Gait Outcomes Evolve in Adults with Spastic Cerebral Palsy Who Received Orthopedic Treatment in Childhood?Children (Basel, Switzerland) · 2026Article
- Functional Electrical Stimulation (FES) in Adults with Neurological Disorders and Foot Drop: Orthotic and Therapeutic Effects in Short- and Long-Term Users.Bioengineering (Basel, Switzerland) · 2026Article
- Non-invasive assessment of muscle spasticity in children with cerebral palsy undergoing botulinum toxin treatment using near-infrared spectroscopy.Journal of neuroengineering and rehabilitation · 2025Article
- Clinical Gait Evaluation with Neuromuscular Impairments (Clinical GENI) for spastic cerebral palsy.Frontiers in human neuroscience · 2025Article
- Lower Extremity Musculoskeletal Complications of Spastic Cerebral Palsy.Journal of orthopaedics and sports medicine · 2025Article
- Unmasking genetic etiologies in neurodevelopmental disorders characterized by Cerebral Palsy: insights from integrative genomic approaches.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Identification of neuromuscular impairments in cerebral palsy (CP) is essential to providing effective treatment. However, clinical recognition of neuromuscular impairments in CP and their contribution to gait abnormalities is limited, resulting in suboptimal treatment outcomes. While CP is the most common childhood movement disorder, clinical evaluations often do not accurately identify and delineate the primary neuromuscular and secondary musculoskeletal impairments or their specific impact on mobility. Here we discuss the primary neuromuscular impairments of CP that arise from early brain injury and the progressive secondary musculoskeletal impairments, with a focus on spastic CP, the most common form of CP. Spastic CP is characterized by four primary interrelated neuromuscular impairments: 1. muscle weakness, 2. short muscle-tendon units due to slow muscle growth relative to skeletal growth, 3. muscle spasticity characterized by increased sensitivity to stretch, and 4. impaired selective motor control including flexor and extensor muscle synergies. Specific gait events are affected by the four primary neuromuscular impairments of spastic CP and their delineation can improve evaluation to guide targeted treatment, prevent deformities and improve mobility. Emerging information on neural correlates of neuromuscular impairments in CP provides the clinician with a more complete context with which to evaluate and develop effective treatment plans. Specifically, addressing the primary neuromuscular impairments and reducing secondary musculoskeletal impairments are important treatment goals. This perspective on neuromuscular mechanisms underlying gait abnormalities in spastic CP aims to inform clinical evaluation of CP, focus treatment more strategically, and guide research priorities to provide targeted treatments for CP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.